natgillin/translations-raw huggingface dataset:
This is thought to lead to increases in the levels of dopamine and noradrenaline between nerve cells in the areas of the brain that are involved in the
Domneva se, da to vodi v povečane ravni dopamina in noradrenalina med živčnimi celicami v delu možganov, ki sodeluje pri nadzoru razpoloženja.
The effects of Thymanax were first tested in experimental models before being studied in humans.
Učinki zdravila Thymanax so bili najprej preizkušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
Thymanax has been compared with placebo (a dummy treatment) in five main short-term studies involving a total of 1,893 adults with major depression.
Zdravilo Thymanax so primerjali s placebom (navideznim zdravilom) v petih glavnih kratkotrajnih študijah, ki so vključevale skupno 1 893 odraslih s hudo depresijo.
Three of these studies included some patients treated with other antidepressants, either fluoxetine or paroxetine, as an ‘ active comparator’.
Tri od teh študij so vključevale nekatere bolnike, zdravljene z drugimi antidepresivi, s fluoksetinom ali paroksetinom, kot „ aktivnim primerjalnim zdravilom “.
The active comparator groups were included to check that the study was able to measure the effectiveness of medicines in treating depression.
Skupine za aktivno primerjavo so vključili, da bi preverili, ali je bilo v študiji mogoče izmeriti učinkovitost zdravil pri zdravljenju depresije.
The main measure of effectiveness in these five studies was the change in symptoms after six weeks, as measured on a standard scale for depression called the Hamilton Depression Rating Scale (HAM-D).
Glavno merilo učinkovitosti v teh petih študijah je bila sprememba simptomov po šestih tednih, merjenih po standardni lestvici merjenja depresije, imenovani Hamiltonova lestvica za merjenje depresije (HAM- D).
The company also presented the results of a further study comparing Thymanax with sertraline (another antidepressant).
Družba je prav tako predstavila rezultate nadaljnje študije, v kateri so zdravilo Thymanax primerjali s sertralinom (drugim antidepresivom).
Two other main studies compared the ability of Thymanax and placebo to prevent symptoms returning in 706 patients whose depression had already been controlled with Thymanax.
V dveh drugih glavnih študijah so primerjali učinkovitost zdravila Thymanax in placeba pri preprečevanju ponovnega pojava simptomov pri 706 bolnikih, pri katerih so depresijo že nadzorovali z zdravilom Thymanax.
In the other three studies, which did include an active comparator, there were no differences in scores between the patients taking Thymanax and those taking placebo.
V ostalih treh študijah, ki so vključevale aktivno primerjalno zdravilo, razlik v rezultatih med bolniki, ki so jemali zdravilo Thymanax, in tistimi, ki so jemali placebo, ni bilo.
However, no effect of fluoxetine or paroxetine was seen in two of these studies, making the results difficult to interpret.
Vendar pa je glede na to, da v dveh izmed teh študij niso bili ugotovljeni nobeni učinki fluoksetina ali paroksetina, te rezultate težko pojasniti.
The additional study showed that agomelatine was more effective than sertraline, with a difference in HAM-D scores of 1.68 after six weeks.
Dodatna študija je pokazala, da je bil agomelatin učinkovitejši od sertralina, z razliko v vrednosti 1, 68 po Hamiltonovi lestvici za merjenje depresije po šestih tednih.
In the first of the long-term studies, there was no difference between Thymanax and placebo in preventing symptoms returning during 26 weeks of treatment.
V prvi izmed dolgotrajnih študij razlike med zdravilom Thymanax in placebom pri preprečevanju vrnitve simptomov v obdobju 26 tednov zdravljenja ni bilo.
However, the second study showed that symptoms returned in 21% of the patients taking Thymanax over 24 weeks (34 out of 165), compared with 41% of the patients taking placebo (72 out of 174).
Vendar pa je druga študija pokazala, da so se simptomi ponovno pojavili pri 21% bolnikov, ki so jemali zdravilo Thymanax dlje od 24 tednov (34 od 165), medtem ko je delež pri bolnikih, ki so jemali placebo, znašal 41% (72 od 174).
The most common side effects with Thymanax (seen in between 1 and 10 patients in 100) are headache, dizziness, somnolence (sleepiness), insomnia (difficulty sleeping), migraine, nausea (feeling sick), diarrhoea, constipation, upper abdominal pain (tummy ache), hyperhidrosis (excessive sweating), back pain, fatigue (tiredness), increases in liver enzymes and anxiety.
Najpogostejši neželeni učinki zdravila Thymanax (opaženi pri 1 do 10 bolnikih izmed 100) so glavobol, vrtoglavica, zaspanost, nespečnost, migrena, navzeja (slabost), diareja, zaprtje, bolečina v zgornjem delu trebuha, hiperhidroza (pretirano znojenje), bolečina v hrbtu, utrujenost, povečana raven jetrnih encimov in anksioznost.
Most side effects were mild or moderate in intensity and happened within the first two weeks of treatment.
Večina neželenih učinkov je bila blagih ali zmernih, pojavili pa so se v prvih dveh tednih zdravljenja.
Some of these side effects may be linked to the patient’ s depression rather than Thymanax itself.
Nekatere od teh neželenih učinkov je mogoče povezati z bolnikovo depresijo, in ne s samim zdravilom Thymanax.
For the full list of all side effects reported with Thymanax, see the Package Leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Thymanax, glejte navodilo za uporabo.
Thymanax should not be used in people who may be hypersensitive (allergic) to agomelatine or any of the other ingredients.
Zdravila Thymanax ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) agomelatin ali katero koli drugo sestavino zdravila.
It must not be used in patients who have problems with their liver, such as cirrhosis (scarring of the liver) or active liver disease.
Ne sme se uporabljati pri bolnikih z jetrnimi težavami, kot so ciroza (brazgotinjenje jeter) ali aktivne bolezni jeter.
It must also not be used in patients who are taking medicines that slow down the breakdown of Thymanax in the body, such as fluvoxamine (another antidepressant) and ciprofloxacin (an antibiotic).
Prav tako ga ne smejo uporabljati bolniki, ki jemljejo zdravila, kot sta fluvoksamin (drug antidepresiv) in ciprofloksacin (antibiotik), ki upočasnijo presnovo zdravila Thymanax v telesu.
Thymanax should not be used in elderly patients with dementia.
Zdravilo Thymanax se ne sme uporabljati pri starejših bolnikih z demenco.
The Committee for Medicinal Products for Human Use (CHMP) noted that Thymanax’ s benefits in terms of treating depression might be lower than seen with other antidepressants.
Odbor za zdravila za uporabo v humani medicini (CHMP) je upošteval, da so koristi zdravila Thymanax pri zdravljenju depresije lahko manjše kot pri drugih antidepresivih.
However, since the medicine has a new mode of action, few side effects and a different safety profile to existing antidepressants, the Committee concluded that Thymanax could be a valuable treatment for some patients as long as their liver function is tested frequently.
Vendar pa je Odbor, glede na nov način delovanja zdravila, malo neželenih učinkov in varnostni profil, drugačen kot pri obstoječih antidepresivih, zaključil, da bi zdravilo Thymanax lahko bilo pomembno za zdravljenje nekaterih bolnikov, pri čemer bi bilo treba redno preverjati njihovo delovanje jeter.
Therefore, the CHMP decided that Thymanax’ s benefits are greater than its risks for the treatment of major depressive episodes in adults.
Zato je CHMP zaključil, da so koristi zdravila Thymanax za zdravljenje hudih epizod depresije pri odraslih večje od z njim povezanih tveganj.
The Committee recommended that Thymanax be given marketing authorisation.
Odbor je priporočil, da se za zdravilo Thymanax odobri dovoljenje za promet.
2/ 3 Which measures are being taken to ensure the safe use of Thymanax?
2/ 3 Kateri ukrepi se izvajajo za zagotovitev varne uporabe zdravila Thymanax?
The company that makes Thymanax will supply educational material for prescribers of Thymanax when it is launched.
Družba, ki izdeluje zdravilo Thymanax, bo ob začetku njegovega trženja za osebe, ki zdravilo Thymanax predpisujejo, zagotovila izobraževalno gradivo.
This material will explain the safety of the medicine, particularly its possible effects on the liver and its interactions with other medicines.
V gradivu bo pojasnjena varnost zdravila, zlasti možni učinki na jetra in medsebojno delovanje z drugimi zdravili.
Other information about Thymanax:
Druge informacije o zdravilu Thymanax:
The European Commission granted a marketing authorisation valid throughout the European Union for Thymanax to Servier (Ireland) Industries Ltd on 19 February 2009.
Evropska komisija je dovoljenje za promet z zdravilom Thymanax, veljavno po vsej Evropski uniji, odobrila družbi Servier (Ireland) Industries Ltd dne februarja 2009.
The full EPAR for Thymanax can be found here.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Thymanax je na voljo tukaj.
EU Procedure number EU/ 1/ 08/ 498/ 001 EU/ 1/ 08/ 498/ 002 EU/ 1/ 08/ 498/ 003 EU/ 1/ 08/ 498/ 004 EU/ 1/ 08/ 498/ 005 EU/ 1/ 08/ 498/ 006 EU/ 1/ 08/ 498/ 007 EU/ 1/ 08/ 498/ 008
EU/ 1/ 08/ 498/ 005 EU/ 1/ 08/ 498/ 006 EU/ 1/ 08/ 498/ 007 EU/ 1/ 08/ 498/ 008
Invented name Thymanax Thymanax Thymanax Thymanax Thymanax Thymanax Thymanax Thymanax
Thymanax Thymanax Thymanax Thymanax
Strength 25 mg 25 mg 25 mg 25 mg 25 mg 25 mg 25 mg 25 mg
25 mg 25 mg 25 mg 25 mg
Pharmaceutical form Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet
Filmsko obložena tableta Filmsko obložena tableta Filmsko obložena tableta Filmsko obložena tableta
Route of administration Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use
Peroralna uporaba Peroralna uporaba Peroralna uporaba Peroralna uporaba
Packaging Blister (alu/ PVC) Blister (alu/ PVC) Blister (alu/ PVC) Blister (alu/ PVC) Blister (alu/ PVC) Blister (alu/ PVC) Blister (alu/ PVC) Blister (alu/ PVC)
Pretisni omot (alu/ PVC) Pretisni omot (alu/ PVC) Pretisni omot (alu/ PVC) Pretisni omot (alu/ PVC)
Package size 7 14 28 42 56 84 98 100
56 84 98 100
1 1 NAME OF THE MEDICINAL PRODUCT
IME ZDRAVILA
Excipient: lactose monohydrate 61.84 mg
61, 84 mg laktoze monohidrata.
Orange-yellow, oblong, film-coated tablet with blue imprint of company logo on one side.
filmsko obložena tableta [tableta] Oranžnorumena, podolgovata, filmsko obložena tableta z modrim odtisom logotipa podjetja na eni strani.
Treatment of major depressive episodes in adults
Zdravljenje velikih depresivnih epizod pri odraslih.
After two weeks of treatment, if there is no improvement of symptoms, the dose may be increased to 50 mg once daily, i. e. two 25 mg tablets, taken together at bedtime.
Če se simptomi ne izboljšajo, lahko po 2 tednih zdravljenja odmerek zvečate na 50 mg enkrat na dan, se pravi dve tableti po 25 mg naenkrat pred spanjem.
Liver function tests should be performed in all patients: at initiation of treatment, and then periodically after around six weeks (end of acute phase), twelve weeks and twenty four weeks (end of maintenance phase) and thereafter when clinically indicated (see also section 4.4).
Delovanje jeter morate pregledovati pri vseh bolnikih: ob uvedbi zdravljenja in nato redno, po približno 6 tednih (na koncu akutne faze), 12 tednih in 24 tednih (na koncu vzdrževalne faze) ter pozneje, ko je to klinično indicirano (glejte tudi poglavje 4. 4).
Thymanax tablets may be taken with or without food.
Tablete zdravila Thymanax lahko bolniki jemljejo s hrano ali brez nje.
Thymanax is not recommended for use in children and adolescents below 18 years of age due to a lack of data on safety and efficacy (see section 4.4).
Otroci in mladostniki Zaradi pomanjkanja podatkov o varnosti in učinkovitosti uporaba zdravila Thymanax pri otrocih in mladostnikih pod 18 let ni priporočljiva (glejte poglavje 4. 4).
Efficacy has not been clearly demonstrated in the elderly (≥ 65 years).
Starejši bolniki Pri starostnikih (≥ 65 let) učinkovitosti niso jasno dokazali.
Only limited clinical data is available on the use of Thymanax in elderly patients ≥ 65 years old with major depressive episodes.
O zdravljenju z zdravilom Thymanax pri bolnikih z depresijo, starih ≥ 65 let, so na voljo le omejeni klinični podatki.
Therefore, caution should be exercised when prescribing Thymanax to these patients (see section 4.4).
Pri predpisovanju zdravila Thymanax tem bolnikom morate biti previdni (glejte poglavje 4. 4).
No relevant modification in agomelatine pharmacokinetic parameters in patients with severe renal impairment has been observed.
Bolniki z ledvično okvaro Pomembnih sprememb farmakokinetičnih parametrov agomelatina pri bolnikih s hudo ledvično okvaro niso opazili.
Therefore, caution should be exercised when prescribing Thymanax to these patients.
Klinični podatki o predpisovanju zdravila Thymanax pri bolnikih z depresijo in hudo ali zmerno ledvično okvaro pa so omejeni, zato morate biti pri predpisovanju zdravila Thymanax tem bolnikom previdni.
2 Thymanax is contraindicated in patients with hepatic impairment (see sections 4.3, 4.4 and 5.2).
2 Zdravilo Thymanax je pri bolnikih z jetrno okvaro kontraindicirano (glejte poglavja 4. 3, 4. 4 in 5. 2).
No dosage tapering is needed on treatment discontinuation.
Prekinitev zdravljenja Ob prekinitvi zdravljenja odmerka ni potrebno postopoma zmanjševati.
Hepatic impairment (i. e. cirrhosis or active liver disease) (see sections 4.2 and 4.4).
Jetrna okvara (na primer ciroza ali aktivne bolezni jeter) (glejte poglavji 4. 2 in 4. 4).
Concomitant use of potent CYP1A2 inhibitors (e. g. fluvoxamine, ciprofloxacin) (see section 4.5).
Sočasno jemanje močnih zaviralcev CYP1A2 (npr. fluvoksamin in ciprofloksacin) (glejte poglavje 4. 5).
Thymanax is not recommended in the treatment of depression in patients under 18 years of age since safety and efficacy of Thymanax have not been established in this age group.
Uporaba pri otrocih in mladostnikih Zdravilo Thymanax ni priporočljivo za zdravljenje depresije pri bolnikih, ki so mlajši od 18 let, ker varnosti in učinkovitosti zdravila Thymanax pri tej starostni skupini niso proučevali.
In clinical trials among children and adolescents treated with other antidepressants, suicide-related behaviour (suicide attempt and suicidal thoughts), and hostility (predominantly aggression, oppositional behaviour and anger) were more frequently observed compared to those treated with placebo.
Samomorilno vedenje (poskuse samomora in samomorilne misli) ter sovražnost (predvsem napadalnost, nasprotovalno vedenje in jezo) so v kliničnih študijah pogosteje opažali pri otrocih ter mladostnikih, zdravljenih z drugimi antidepresivi, kot pri tistih, ki so jemali placebo.
Thymanax should not be used for the treatment of major depressive episodes in elderly patients with dementia since the safety and efficacy of Thymanax have not been established in these patients.
Uporaba pri starejših bolnikih z demenco Zdravila Thymanax ne smete predpisovati za zdravljenje velikih depresivnih epizod pri starejših bolnikih z demenco, ker varnosti in učinkovitosti zdravila Thymanax pri tovrstnih bolnikih niso proučevali.
Thymanax should be used with caution in patients with a history of mania or hypomania and should be discontinued if a patient develops manic symptoms.
Manija / hipomanija Pri bolnikih z manijo ali hipomanijo v anamnezi morate zdravilo Thymanax uporabljati previdno in zdravljenje prekiniti, če se pri bolniku razvijejo simptomi manije.
Depression is associated with an increased risk of suicidal thoughts, self harm and suicide (suicide- related events).
Samomor / samomorilne misli Depresija je povezana z večjim tveganjem za pojav samomorilnih misli, samopoškodovanja in samomorilnosti (s samomorom povezani dogodki).
Close supervision of patients and in particular those at high risk should accompany treatment especially in early treatment and following dose changes.
Še posebej skrbno je treba nadzirati bolnike z velikim tveganjem.
Combination with CYP1A2 inhibitors (see sections 4.3 and 4.5) Combination with potent CYP1A2 inhibitors is contraindicated.
Kombinacija z zaviralci CYP1A2 (glejte poglavji 4. 3 in 4. 5) Kombinacija z močnimi zaviralci CYP1A2 je kontraindicirana.
Caution should be exercised when prescribing Thymanax with moderate CYP1A2 inhibitors (e. g. propranolol, grepafloxacine, enoxacine) which may result in increased exposure of agomelatine.
Pri sočasnem predpisovanju zdravila Thymanax z zmernimi zaviralci CYP1A2 (npr. propranololom, grepafloksacinom, enoksacinom) morate biti previdni, saj se lahko zveča izpostavljenost agomelatinu.
In clinical studies, elevations of serum transaminases (> 3 times the upper limit of the normal range) have been observed in patients treated with Thymanax particularly on a 50 mg dose (see section 4.8).
Zvečanje transaminaz v serumu V kliničnih študijah so pri bolnikih, ki so jemali zdravilo Thymanax, zlasti v odmerku 50 mg, opažali zvečanje transaminaz v serumu (> 3- kratna zgornja meja normalnega razpona) (glejte poglavje 4. 8).
When Thymanax was discontinued in these patients, the serum transaminases usually returned to normal levels.
Ko so pri teh bolnikih zdravilo Thymanax ukinili, so se transaminaze v serumu običajno vrnile na
Any patient who develops
Delovanje jeter morate pregledovati pri vseh bolnikih: ob uvedbi zdravljenja in nato redno, po približno 6 tednih (na koncu akutne faze), 12 tednih in 24 tednih (na koncu vzdrževalne faze) ter pozneje, ko je to klinično indicirano.
3 increased serum transaminases should have his/ her liver function tests repeated within 48 hours.
Če pri kateremkoli bolniku opazite zvečanje transaminaz v serumu, morate pregled delovanja jeter ponoviti v 48 urah.
Therapy should be discontinued if the increase in serum transaminases exceeds 3X upper limit of normal and liver function tests should be performed regularly until serum transaminases return to normal.
Če zvečanje transaminaz v serumu presega 3- kratno zgornjo mejo normalnih vrednosti, morate zdravljenje prekiniti in redno pregledovati delovanje jeter, dokler se vrednost transaminaz v serumu ne normalizira.
If any patient develops symptoms suggesting hepatic dysfunction liver function tests should be performed.
Če se pri kateremkoli bolniku pojavijo simptomi, ki kažejo na jetrno popuščanje, morate pregledati delovanje jeter.
The decision whether to continue the patient on therapy with Thymanax should be guided by clinical judgement pending laboratory evaluations.
O nadaljevanju zdravljenja z zdravilom Thymanax se odločate po klinični presoji glede na rezultate laboratorijskih preiskav.
If jaundice is observed therapy should be discontinued.
Če opazite zlatenico, morate prekiniti zdravljenje.
Caution should be exercised when Thymanax is administered to patients who consume substantial quantities of alcohol or who are treated with medicinal products associated with risk of hepatic injury.
Če bolniki pijejo znatne količine alkohola ali jemljejo zdravila, ki jih spremlja tveganje za poškodbe jeter, morate biti pri predpisovanju zdravila Thymanax previdni.
Thymanax contains lactose.
Intoleranca za laktozo Zdravilo Thymanax vsebuje laktozo.
Agomelatine is metabolised mainly by cytochrome P450 1A2 (CYP1A2) (90%) and by CYP2C9/ 19 (10%).
Možna medsebojna delovanja, ki vplivajo na agomelatin Agomelatin se presnavlja predvsem preko citokroma P450 1A2 (CYP1A2) (90%) in CYP2C9/ 19 (10%).
Fluvoxamine, a potent CYP1A2 and moderate CYP2C9 inhibitor markedly inhibits the metabolism of agomelatine resulting in a 60-fold (range 12-412) increase of agomelatine exposure.
Fluvoksamin, močan zaviralec CYP1A2 in zmeren zaviralec CYP2C9, izrazito zavira presnovo agomelatina, zaradi česar se izpostavljenost agomelatinu zveča za 60- krat (razpon:
Consequently, co-administration of Thymanax with potent CYP1A2 inhibitors (e. g. fluvoxamine, ciprofloxacin) is contraindicated.
Sočasno jemanje agomelatina z močnimi zaviralci CYP1A2 (npr. fluvoksaminom in ciprofloksacinom) je zato kontraindicirano.
While there was no specific safety signal in the 800 patients treated in combination with oestrogens, caution should be exercised when prescribing agomelatine with other moderate CYP1A2 inhibitors (e. g. propranolol, grepafloxacine, enoxacine) until more experience has been gained (see section 4.4).
Čeprav pri 800 bolnikih, ki so sočasno jemali estrogene, niso zasledili specifičnih varnostnih opozoril, morate biti previdni, ko predpisujete agomelatin z drugimi zmernimi zaviralci CYP1A2 (npr. propranololom, grepafloksacinom, enoksacinom), dokler ne bo na voljo več izkušenj (glejte poglavje 4. 4).
In vivo, agomelatine does not induce CYP450 isoenzymes.
Možen vpliv agomelatina na druga zdravila In vivo, agomelatin ne spodbuja izoencimov CYP450.
Agomelatine does not modify free concentrations of medicinal products highly bound to plasma proteins or vice versa.
Zdravila z veliko vezavo na beljakovine v plazmi Agomelatin ne vpliva na proste koncentracije zdravil z veliko vezavo na beljakovine v plazmi ali obratno.
No evidence of pharmacokinetic or pharmacodynamic interaction with medicinal products which could be prescribed concomitantly with Thymanax in the target population was found in phase I clinical trials: benzodiazepines, lithium, paroxetine, fluconazole and theophylline.
Druga zdravila V kliničnih preskušanjih faze I niso opazili dokazov o farmakokinetičnem ali famakodinamičnem medsebojnem delovanju zdravila Vadoxan z zdravili, ki jih sočasno predpisujemo pri ciljni skupini bolnikov: benzodiazepini, litijem, paroksetinom, flukonazolom in teofilinom.
The combination of Thymanax and alcohol is not advisable.
Alkohol Sočasno jemanje zdravila Thymanax z alkoholom ni priporočljivo.
There is no experience of concurrent use of agomelatine with ECT.
Elektrokonvulzivno zdravljenje Ni izkušenj z jemanjem agomelatina sočasno z elektrokonvulzivnim zdravljenjem.
Therefore, clinical consequences of ECT concomitant treatment with Thymanax are considered to be unlikely.
Študije na živalih niso pokazale prokonvulzivnih lastnosti (glejte poglavje 5. 3), zato ni verjetno, da bi se zaradi sočasnega elektrokonvulzivnega zdravljenja in jemanja zdravila Thymanax pojavljale klinične posledice.
4 or postnatal development (see section 5.3).
4 O izpostavljenosti agomelatinu med nosečnostjo ni podatkov.
Caution should be exercised when prescribing to pregnant women.
Študije na živalih ne kažejo na neposredne ali posredne škodljive vplive na nosečnost, razvoj zarodka/ plodu, porod ali postnatalni razvoj (glejte poglavje 5. 3).
It is not known whether agomelatine is excreted into human milk.
Ni znano, ali se agomelatin izloča v materino mleko.
Agomelatine or its metabolites are excreted in the milk of lactating rats.
Agomelatin in njegovi presnovki se izločajo v mleko doječih podgan.
Potential effects of agomelatine on the breast-feeding infant have not been established.
Morebitnih učinkov agomelatina na dojeno potomstvo niso opažali.
If treatment with Thymanax is considered necessary, breastfeeding should be discontinued.
Če je zdravljenje z zdravilom Thymanax potrebno, mora mati prekiniti z dojenjem.
In clinical trials, over 3,900 depressed patients have received Thymanax.
Zdravilo Thymanax je v kliničnih preskušanjih jemalo več kot 3. 900 bolnikov z depresijo.
Depressed patients display a number of symptoms that are associated with the illness itself.
Bolniki z depresijo imajo vrsto simptomov, ki so povezani s samo boleznijo.
It is therefore sometimes difficult to ascertain which symptoms are a result of the illness itself and which are a result of treatment with Thymanax.
Včasih je zato težko ločiti med simptomi, ki jih povzroča sama bolezen in tistimi, ki nastanejo zaradi zdravljenja z zdravilom Thymanax.